Target Name: URI1
NCBI ID: G8725
Review Report on URI1 Target / Biomarker Content of Review Report on URI1 Target / Biomarker
URI1
Other Name(s): URI1 prefoldin like chaperone, transcript variant 1 | Unconventional prefoldin RPB5 interactor 1 | RNA polymerase II subunit 5-mediating protein | RMP_HUMAN | Unconventional prefoldin RPB5 interactor | PPP1R19 | RNA polymerase II, subunit 5-mediating protein | URI | Protein NNX3 | Unconventional prefoldin RPB5 interactor 1 (isoform a) | protein phosphatase 1, regulatory subunit 19 | RPB5-mediating protein | URI1 variant 1 | C19orf2 | RMP | NNX3 | FLJ10575 | Protein phosphatase 1 regulatory subunit 19 | URI1 prefoldin like chaperone

URI1: A Potential Drug Target and Biomarker

URI1 (Ubiquitin-associated protein 1) is a protein that plays a crucial role in the regulation of protein-protein interactions, which are essential for various cellular processes, including cell signaling, DNA replication, and response to stress. URI1 is a member of the superfamily of chaperone proteins, which include a variety of structurally similar proteins that assist in protein-protein interactions and can form a covalent complex with other proteins. URI1 is unique in that it is a small molecule that can interact with its target proteins and regulate their stability.

URI1 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for human health. URI1 has been shown to play a role in the regulation of the immune response, specifically in the regulation of T cell proliferation and differentiation. URI1 has also been shown to play a role in the regulation of cell signaling pathways, including the regulation of cell proliferation, apoptosis, and angiogenesis.

URI1 has also been identified as a potential biomarker for various diseases, including cancer. URI1 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, studies have shown that URI1 is involved in the regulation of cancer cell migration and invasion, which may have implications for the development of new cancer therapies.

The Structure and Function of URI1

URI1 is a small protein that is expressed in various cellular organelles, including the endoplasmic reticulum, the cytoplasm, and the mitochondria. URI1 has a unique structure that is composed of a long amino acid sequence that is terminated by a polyhistidine residue. The polyhistidine residue is known for its ability to form a covalent complex with other proteins, which is a key feature that allows URI1 to interact with its target proteins.

The function of URI1 is to regulate protein-protein interactions by forming a covalent complex with its target proteins. URI1 has been shown to interact with a wide variety of proteins, including other chaperone proteins, transcription factors, and signaling proteins. URI1 has been shown to regulate the stability of its target proteins by affecting their levels of stability and stability interactions.

URI1 has also been shown to play a role in the regulation of cellular processes that are important for human health. For example, URI1 has been shown to play a role in the regulation of the immune response, specifically in the regulation of T cell proliferation and differentiation. URI1 has also been shown to play a role in the regulation of cell signaling pathways, including the regulation of cell proliferation, apoptosis, and angiogenesis.

URI1 as a Potential Drug Target

URI1 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for human health. One of the potential mechanisms by which URI1 can be targeted is by small molecules that can interact with URI1 and disrupt its function. This can lead to the inhibition of URI1-mediated protein-protein interactions, which can have a negative impact on the stability and function of the target proteins.

URI1 has also been shown to play a role in the regulation of cancer cell migration and invasion, which may have implications for the development of new cancer therapies. Therefore, targeting URI1 with small molecules or other therapeutic agents may be a promising strategy for the treatment of various types of cancer.

URI1 as a Potential Biomarker

URI1 has also been identified as a potential biomarker for various diseases, including cancer. URI1 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, studies have shown that URI1 is involved in the regulation of cancer cell migration and invasion, which may have implications for the development of new cancer therapies. Therefore, measuring the levels of URI1 in cancer cells or in patient samples may be a promising strategy for the diagnosis and prognosis of various types of cancer.

Conclusion

URI1 is a protein that plays a crucial

Protein Name: URI1 Prefoldin Like Chaperone

Functions: Involved in gene transcription regulation. Acts as a transcriptional repressor in concert with the corepressor UXT to regulate androgen receptor (AR) transcription. May act as a tumor suppressor to repress AR-mediated gene transcription and to inhibit anchorage-independent growth in prostate cancer cells. Required for cell survival in ovarian cancer cells. Together with UXT, associates with chromatin to the NKX3-1 promoter region. Antagonizes transcriptional modulation via hepatitis B virus X protein

The "URI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about URI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

Uridine phosphorylase | URM1 | UROC1 | UROD | UROS | USB1 | USE1 | USF1 | USF2 | USF3 | USH1C | USH1G | USH2A | USHBP1 | USO1 | USP1 | USP1-UAF1 complex | USP10 | USP11 | USP12 | USP12-AS1 | USP12-DT | USP13 | USP14 | USP15 | USP16 | USP17L1 | USP17L10 | USP17L11 | USP17L12 | USP17L13 | USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7